Richard Bryan Riggsbee net worth and biography

Richard Riggsbee Biography and Net Worth

Bryan Riggsbee, chief financial officer, joined Myriad Genetics in October 2014. He previously served 10 years with Laboratory Corporation of America (LabCorp) where his most recent position was as senior vice president of Corporate Finance with responsibility for the financial planning and analysis and treasury functions. Prior to LabCorp, Mr. Riggsbee served in various finance roles with General Electric and began his career in the audit division of KPMG. He received a B.A. degree in Accounting from North Carolina State University, a B.A. degree in Political Science from the University of North Carolina at Chapel Hill and an M.B.A. from Northwestern University. Mr. Riggsbee is a Certified Public Accountant licensed in the State of North Carolina.

What is Richard Bryan Riggsbee's net worth?: The estimated net worth of Richard Bryan Riggsbee is at least $5.98 million as of November 1st, 2023. Mr. Riggsbee owns 321,812 shares of Myriad Genetics stock worth more than $5,982,485 as of April 18th. This net worth estimate does not reflect any other assets that Mr. Riggsbee may own. Learn More about Richard Bryan Riggsbee's net worth.
How do I contact Richard Bryan Riggsbee?: The corporate mailing address for Mr. Riggsbee and other Myriad Genetics executives is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. Myriad Genetics can also be reached via phone at (801) 584-3600 and via email at [email protected]. Learn More on Richard Bryan Riggsbee's contact information.
Has Richard Bryan Riggsbee been buying or selling shares of Myriad Genetics?: Richard Bryan Riggsbee has not been actively trading shares of Myriad Genetics within the last three months. Most recently, Richard Bryan Riggsbee sold 30,000 shares of the business's stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $15.69, for a transaction totalling $470,700.00. Following the completion of the sale, the chief financial officer now directly owns 321,812 shares of the company's stock, valued at $5,049,230.28. Learn More on Richard Bryan Riggsbee's trading history.
Who are Myriad Genetics' active insiders?: Myriad Genetics' insider roster includes Jayne Hart (Insider), Nicole Lambert (Insider), Jerry Lanchbury (Insider), Dennis Langer (Director), S. Phanstiel (Director), Richard Riggsbee (CFO), and Daniel Spiegelman (Director). Learn More on Myriad Genetics' active insiders.
Are insiders buying or selling shares of Myriad Genetics?: In the last twelve months, insiders at the sold shares 2 times. They sold a total of 38,638 shares worth more than $669,460.38. The most recent insider tranaction occured on November, 1st when CFO Richard Bryan Riggsbee sold 30,000 shares worth more than $470,700.00. Insiders at Myriad Genetics own 2.0% of the company. Learn More about insider trades at Myriad Genetics.
Information on this page was last updated on 11/1/2023.

Richard Bryan Riggsbee Insider Trading History at Myriad Genetics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/1/2023	Sell	30,000	$15.69	$470,700.00	321,812
1/20/2023	Sell	9,400	$20.04	$188,376.00	364,107
1/18/2023	Sell	600	$20.01	$12,006.00	373,507
12/27/2022	Sell	20,000	$15.15	$303,000.00	374,107
8/3/2021	Sell	14,983	$35.14	$526,502.62	324,942
8/1/2019	Sell	25,000	$41.50	$1,037,500.00	120,566

Richard Bryan Riggsbee Buying and Selling Activity at Myriad Genetics

Myriad Genetics Company Overview

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Today's Range

Now: $18.59

$18.21

$18.91

50 Day Range

MA: $21.68

$18.64

$23.59

2 Week Range

Now: $18.59

$13.82

$24.21

Volume

279,269 shs

Average Volume

623,749 shs

Market Capitalization

$1.67 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.95

AI “wealth window” is closing soon!

From Paradigm Press | Ad

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…